We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01293448
Recruitment Status : Completed
First Posted : February 10, 2011
Last Update Posted : April 28, 2022
Sponsor:
Information provided by (Responsible Party):
Pentax Medical

Brief Summary:
The purpose of this study is to evaluate a cryoablation technique used to ablate human esophageal mucosa.

Condition or disease Intervention/treatment Phase
Barrett's Esophagus Esophageal Cancer Device: Cryoballoon Ablation Not Applicable

Detailed Description:
The purpose of this study is to evaluate the histological results of a cryoablation technique used to ablate human esophageal mucosa. The performance and safety of the cryoablation technique will also be evaluated.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 21 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Balloon-based Cryoablation of Human Esophageal Epithelium
Study Start Date : December 2010
Actual Primary Completion Date : January 2012
Actual Study Completion Date : January 2012

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Intervention
CryoBalloon ablation of esophageal tissue in patients scheduled for esophagectomy for reasons unrelated to the objective of the study.
Device: Cryoballoon Ablation
Device: CryoBalloon Ablation System(TM) C2 Therapeutics Inc. received FDA market clearance for the CryoBalloon Ablation System on September 29, 2010. The System is a Class II device "intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications." (K101825)
Other Names:
  • CryoBalloon Ablation System
  • cryoablation




Primary Outcome Measures :
  1. Treatment effect [ Time Frame: Within 30 days of ablation procedure ]
    The primary outcome measure is to evaluate the histological results (depth of injury) of a cryoballoon ablation system.


Secondary Outcome Measures :
  1. Post-ablation symptoms [ Time Frame: Within 7 days of ablation procedure ]
    A secondary outcome measure is to evaluate post-ablation symptoms - number of participants with adverse events as a measure of safety and tolerability.

  2. Post procedure pain [ Time Frame: Within 7 days of ablation procedure ]
    The secondary objective of the study is to determine patient comfort post-procedure. Pain scores are measured on a numerical pain intensity scale.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient must have a minimum of 2.0 cm of non-ulcerated, non-inflammatory columnar-lined esophagus or squamous esophageal lined tissue suitable for ablation. A patient may be treated with up to 2 zones of ablation.
  • Patient is 18 to 80 years of age at the time of consent (inclusive).
  • Patient has provided written Informed Consent Form (IFC) using a form that has been approved by the Institution's reviewing IRB/EC.
  • Patient is willing and able to comply with all Clinical Investigation Plan (CIP) requirements.
  • Patient's esophagectomy is clinically necessary due to reasons unrelated to this study.
  • Patient is deemed operable per standard institutional criteria.

Exclusion Criteria:

  • Patient has a known history of unresolved drug or alcohol dependency that would limit ability to comprehend or follow instructions related to IFC, post treatment instructions or follow-up guidelines.
  • Patient refuses or is unable to provide written informed consent. - -
  • Patient has or is currently undergoing endoscopic ablation therapy within 4 cm from the proposed treatment area including, but not limited to cryospray therapy, laser treatment, photodynamic therapy, multi-polar electro coagulation, endoscopic mucosal resection, radiofrequency ablation or argon plasma coagulation.
  • Patient has esophageal narrowing limiting access to the intended site of ablation.
  • Patient is undergoing or has recently undergone chemotherapy (within 15 days or WBC below normal by institutional criteria or standards).
  • Patient is undergoing or has recently undergone radiation therapy which involved the esophagus (within 15 days or WBC below normal by institutional criteria or standards).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01293448


Locations
Layout table for location information
United States, California
University of Southern California
Los Angeles, California, United States, 90033
United States, New York
University of Rochester
Rochester, New York, United States, 14642
United States, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15232
Netherlands
AMC
Amsterdam, AZ, Netherlands, 1105
Sponsors and Collaborators
Pentax Medical
Investigators
Layout table for investigator information
Principal Investigator: Jacques Bergman, MD AIDS Malignancy Consortium
Principal Investigator: Steve DeMeester, MD University of Southern California
Principal Investigator: Blair Jobe, MD University of Pittsburgh
Principal Investigator: Jeffery Peters, MD University of Rochester
Layout table for additonal information
Responsible Party: Pentax Medical
ClinicalTrials.gov Identifier: NCT01293448    
Other Study ID Numbers: CP-0001.A
First Posted: February 10, 2011    Key Record Dates
Last Update Posted: April 28, 2022
Last Verified: January 2018
Keywords provided by Pentax Medical:
Esophagectomy
Barrett's Esophagus
Additional relevant MeSH terms:
Layout table for MeSH terms
Barrett Esophagus
Neoplasms
Digestive System Diseases
Esophageal Diseases
Gastrointestinal Diseases
Precancerous Conditions